Linked Data API

Show Search Form

Search Results

1141958
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Pertuzumab more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what advice they provide to clinicians for the use of Pertuzumab rather than Herceptin for the treatment of HER2+ breast cancer. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL17502 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-25more like thisremove minimum value filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17501 more like this
star this property question first answered
less than 2019-07-25T16:45:03.207Zmore like thismore than 2019-07-25T16:45:03.207Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1141957
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Breast Cancer: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what are the drugs approved by NICE to treat HER2+ breast cancer; and what assessment they have made of the efficacy of such drugs. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL17501 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-25more like thisremove minimum value filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17502 more like this
star this property question first answered
less than 2019-07-25T16:45:03.16Zmore like thismore than 2019-07-25T16:45:03.16Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1141959
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Breast Cancer: Clinical Trials more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government which clinical trials are currently recruiting patients with HER2+ breast cancer. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL17503 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-08-07more like thismore than 2019-08-07
star this property answer text <p>The Department’s National Institute for Health Research (NIHR) is currently recruiting to 15 clinical trials for people with HER2+ breast cancer via its Clinical Research Network. The majority of these are commercially funded. To date, a total of 7,986 participants have been recruited to these 15 trials.</p><p>Of the 15 clinical trials, 12 are commercially sensitive, with appropriate cost recovery from the companies. The data for these commercial trials has been provided from the relevant companies as ‘commercial in confidence’ hence we are unable to provide details about these trials such as their titles.</p><p>However, the three clinical trials which are not commercially sensitive are:</p><p>- Cancer Research UK; NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC). Title: The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices (plasmaMATCH);</p><p>- Cancer Research UK. Title: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer; and</p><p>- Medical Research Council. Title: A mechanistic non-invasive imaging study of HER2 expression in breast cancer using [18F]GE-226 positron emission tomography.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-08-07T11:43:14.327Zmore like thismore than 2019-08-07T11:43:14.327Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this